Create accountLogin

Recent searches

No recent searches

Search options

Only available when logged in.
med-mastodon.com is one of the many independent Mastodon servers you can use to participate in the fediverse.
Medical community on Mastodon

Administered by:

Server stats:

409
active users

med-mastodon.com: AboutProfiles directoryPrivacy policy

Mastodon: AboutGet the appKeyboard shortcutsView source codev4.3.7

#LMICs

0 posts0 participants0 posts today
Public *
petersuber

One year after launch, the #OpenAccess edition of the International Journal of Tuberculosis and Lung Disease finds that "OA is helping us to achieve our goal of improving knowledge dissemination in #LMICs, where there is restricted access to subscription journals. Citation analysis of the first few issues of IJTLD OPEN also suggests that this higher level of downloads [higher than for the non-OA edition] is leading to articles being cited at an accelerated rate."
ingentaconnect.com/content/iua

www.ingentaconnect.comA year in review – evaluating the launch of IJTLD OPEN: Ingenta Connect
#OACA#ScholComm
Continued thread
Public
Jan R. Boehnke

With view to #multimorbidity I focus on work led by Phuong Bich Tran using our COSMOS /
#IMPACTNIHR qualitative data investigating the lived experiences of people living w MM in #LMICs by exploring their perspectives, experiences, and aspirations
gh.bmj.com/content/9/1/e013606

The interviews firstly showed strongly the importance of healthcare cost and forgone income as outcomes of #HealthCare, which are often not considered in the development of core outcome sets (see also medrxiv.org/content/10.1101/20)

BMJ Global Health · An interpretative phenomenological analysis of the lived experience of people with multimorbidity in low- and middle-income countriesPeople living with multimorbidity (PLWMM) have multiple needs and require long-term personalised care, which necessitates an integrated people-centred approach to healthcare. However, people-centred care may risk being a buzzword in global health and cannot be achieved unless we consider and prioritise the lived experience of the people themselves. This study captures the lived experiences of PLWMM in low- and middle-income countries (LMICs) by exploring their perspectives, experiences, and aspirations. We analysed 50 semi-structured interview responses from 10 LMICs across three regions—South Asia, Latin America, and Western Africa—using an interpretative phenomenological analysis approach. The bodily, social, and system experiences of illness by respondents were multidirectional and interactive, and largely captured the complexity of living with multimorbidity. Despite expensive treatments, many experienced little improvements in their conditions and felt that healthcare was not tailored to their needs. Disease management involved multiple and fragmented healthcare providers with lack of guidance, resulting in repetitive procedures, loss of time, confusion, and frustration. Financial burden was exacerbated by lost productivity and extreme finance coping strategies, creating a vicious cycle. Against the backdrop of uncertainty and disruption due to illness, many demonstrated an ability to cope with their conditions and navigate the healthcare system. Respondents’ priorities were reflective of their desire to return to a pre-illness way of life—resuming work, caring for family, and maintaining a sense of independence and normalcy despite illness. Respondents had a wide range of needs that required financial, health education, integrated care, and mental health support. In discussion with respondents on outcomes, it appeared that many have complementary views about what is important and relevant, which may differ from the outcomes established by clinicians and researchers. This knowledge needs to complement and be incorporated into existing research and treatment models to ensure healthcare remains focused on the human and our evolving needs. Data are available upon reasonable request and subject to approval by the COSMOS group. Part of the data is available in online supplemental file 4.
Public *
petersuber

"As part of the #treaty discussions, #LMICs are asking…public #funders of…research to require that…#pandemic-related #drugs…that result from [their] grants be shared equitably during a…health emergency…Funders could…require grantees to openly share study results…Funders could retain certain #IP rights to be used only when [necessary] to develop & distribute products equitably...However, the latest version of the treaty text does not include such provisions."
nature.com/articles/d41586-024

www.nature.comResearch funders must join the fight for equal access to medicinesPandemic treaty is a rare opportunity to ensure pandemic-related technologies are accessible and affordable to all.
#Medicine
Public
Claudia Gonzaga-Jauregui 🧬

Beautiful art work in the latest front cover of @Nature to illustrate the diversity of Mexican Genomics as evidenced by the recent publication of MX Biobank and MCPS. Great genomics resources for a Latin American population, we need more large-scale genomics projects for underrepresented populations, but also the time & resources to analyze, derive and implement insights, and train students to work with these data.
#GenomicEquity #LatinAmerica #LATAM #LMICs #Genomics

Public
IndiaNewsWatch

After Decades of Pressure, US Drugmaker J&J Gives Up Patent on Life-Saving TB Drug

This move can lead to the entry of many manufacturers of bedaquiline, thereby reducing the exorbitant price which many governments currently find difficult to afford for all of their patients, say activists.

thewire.in/health/after-decade

The WireAfter Decades of Pressure, US Drugmaker J&J Gives Up Patent on Life-Saving TB DrugThis move can lead to the entry of many manufacturers of bedaquiline, thereby reducing the exorbitant price which many governments currently find difficult to afford for all of their patients, say activists.
#tuberculosis#JohnsonAndJohnson#bedaquiline
Public *
petersuber

Global research-and-development (R&D) investment works out to $1,286 per capita per year in high-income countries and just $42 in low and middle income countries.
nature.com/articles/d41586-023

The article focuses on "benevolent #patent extension" as a partial remedy. "An inventor who applies to patent a ‘benevolent discovery’ — one that targets LMICs’ needs — [can] offset the R&D costs by extending another patent, for a ‘non-essential’ product."

www.nature.com‘Benevolent’ patent extensions could raise billions for R&D in poorer countriesResearch into vaccines, crop seeds and other innovations for low- or middle-income nations could be rewarded by offering longer patent coverage for profitable, non-essential inventions.
#HICs#LMICs#North
Public *
petersuber

I've seen 3 common explanations for why authors publish in #predatory journals: (1) they're deceived; (2) they're padding their resumes; (3) their work is weak.

This letter proposes a 4th, money.
nature.com/articles/d41586-023
(#paywalled)

"Many scientists from #LMICs…are rewarded with bonuses & promotions by their institutions [when they publish]…Many are likely to consider it worth paying an author publication charge [#APC] of $50 to secure a $300 research bonus for a guaranteed publication."

www.nature.comWhen authors play the predatory journals’ own gameLetter to the Editor
Continued thread
Public *
Shiwali Mohan | शिवाली मोहन

3. Recent #GenerativeAI is one of the most expensive forms of computation to exist. Even for particularly simple problems, it takes significantly more energy.

Without understanding the constraints that exist in medical systems at #LMICs, can we really claim that this technology would be revolutionary?

For #BMGF to support these claims without sufficient critical analysis is counterproductive to both #AI and #HealthCare in #LMICs.

(n/n)

(n/n)

ExploreLive feeds
About